2025 Impact Report
In 2025, families found connection, care expanded, and research accelerated, bringing treatments and a cure closer than ever.
In 2025, families found connection, care expanded, and research accelerated, bringing treatments and a cure closer than ever.
The Phelan-McDermid Syndrome Foundation’s 2025 Independent Audit Report provides an objective assessment of the organization’s financial statements and internal controls.
The Phelan-McDermid Syndrome Foundation (PMSF) is committed to transparency and responsible stewardship.
The Phelan McDermid Syndrome Foundation (PMSF) today announced the appointment of Robbie Baker, a seasoned nonprofit executive and successful fundraiser, as its new Chief Executive Officer.
A new FAQ from Jaguar Gene Therapy is now available, including updated details about the JAG201 clinical study. This FAQ addresses…
This one-page information sheet provides a brief overview of Phelan-McDermid syndrome, including its genetics, symptoms, treatments, and how the Phelan-McDermid Syndrome…
Phelan-McDermid syndrome is characterized by global developmental delay, intellectual disability, speech impairment, autism spectrum disorder, and hypotonia; other variable features include epilepsy, brain and renal malformations, and mild dysmorphic features. Here, we conducted genotype-phenotype correlation analyses using the PMS International Registry, a family-driven registry that compiles clinical data in the form of family-reported outcomes and family-sourced genetic test results.
Phelan-McDermid Syndrome Foundation, Inc. Independent Auditor’s Report, Financial Statements For the years ended December 31, 2023 and 2022
Phelan-McDermid Syndrome Foundation (PMSF) 990 Tax Form
2023 990 Tax Form Signature Page